TetraLogic and Merck will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic's SMAC-mimetic, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with relapsed or refractory solid tumors.
The study is expected to begin in late 2015.
|Searching for more deal information? Current Partnering offers the following options:
TetraLogic and Merck, through subsidiaries, will collaborate on an initial Phase 1 dose-escalation study of birinapant in combination with KEYTRUDA in patients with relapsed or refractory solid tumors.
TetraLogic will sponsor and fund the study and Merck will provide KEYTRUDA.
The companies have formed a Joint Development Committee to collaboratively oversee the conduct of the study.
Results from the study will be used to determine the path for further clinical development of the combination.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies